Status:
COMPLETED
Effect of Nafamostat on Postreperfusion Syndrome (PRS)
Lead Sponsor:
Seoul National University Hospital
Conditions:
Liver Transplantation
Postreperfusion Syndrome
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.
Eligibility Criteria
Inclusion
- \>= 18 year old scheduled to undergo liver transplantation
Exclusion
- Previous history of pulmonary, cardiovascular, or renal disease
- Previous history of allergic reactions to nafamostat
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT01001403
Start Date
March 1 2009
End Date
April 1 2010
Last Update
May 11 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, Seoul, South Korea, 110-744